These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15779438)

  • 1. [Treatment for coronary artery disease patients with impaired glucose tolerance].
    Kume A; Miyazaki T; Daida H
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
    Tomono S; Uchiyama T; Ohyama Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():255-9. PubMed ID: 15779382
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pathophysiological conditions progressing from impaired glucose tolerance: atherosclerosis].
    Yokote K; Saito Y
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():250-4. PubMed ID: 15779381
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 5. [Characteristic of metformin for treatment of impaired glucose tolerance].
    Ishida W; Satoh J
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():433-7. PubMed ID: 15779418
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Inquiries: How can we keep impaired glucose tolerance and impaired fasting glucose from progressing to diabetes?
    Swanson A; Watrin K; Wilder L
    J Fam Pract; 2010 Sep; 59(9):532-3. PubMed ID: 20824232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of type 2 diabetes in the prediabetic population.
    Maji D; Roy RU; Das S
    J Indian Med Assoc; 2005 Nov; 103(11):609-11. PubMed ID: 16570766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevention by life style intervention and medication. To run away from type 2 diabetes].
    Wepner U
    MMW Fortschr Med; 2004 Apr; 146(14):16. PubMed ID: 15344745
    [No Abstract]   [Full Text] [Related]  

  • 10. [Diabetes prevention program (metformin)].
    Kusaka I; Nagasaka S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():471-7. PubMed ID: 15779424
    [No Abstract]   [Full Text] [Related]  

  • 11. [Coronary artery disease in patients with diabetes mellitus and its treatment].
    Teramoto T
    Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():94-9. PubMed ID: 11989270
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impaired glucose tolerance in patients with ischemic heart diseases].
    Yasuda S; Miyazaki S
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():300-2. PubMed ID: 15779392
    [No Abstract]   [Full Text] [Related]  

  • 15. [Childhood obesity increases the risk of coronary artery disease].
    Nuutinen O; Nuutinen M
    Duodecim; 2001; 117(13):1356-62. PubMed ID: 12184126
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus.
    Ravipati G; Aronow WS; Ahn C; Sujata K; Saulle LN; Channamsetty V; Weiss MB
    Am J Ther; 2006; 13(5):400-3. PubMed ID: 16988534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
    Omer Z; Cetinkalp S; Akyildiz M; Yilmaz F; Batur Y; Yilmaz C; Akarca U
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):18-23. PubMed ID: 19667999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impaired glucose tolerance in the pathogenesis of dyslipidemia].
    Ikoue I; Takahashi K; Katayama S
    Nihon Rinsho; 1996 Oct; 54(10):2672-8. PubMed ID: 8914426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hypertensive patients with impaired glucose tolerance (IGT)].
    Yoshida D; Higashiura K; Shimamoto K
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():533-7. PubMed ID: 15779436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.